10-K/A: Azitra Inc. Amends Annual Report to Include Omitted Information

Azitra, Inc. has filed an amendment to its annual report to include previously omitted information regarding directors, executive officers, and corporate governance.

Summary

• Azitra, Inc. filed an amendment to its annual report on Form 10-K to include information previously omitted from the original filing.
• The amendment focuses on Part III, Items 10 through 14, which cover directors, executive officers, corporate governance, executive compensation, security ownership, related transactions, and principal accountant fees.
• The original report was filed on March 15, 2024, and this amendment was filed on April 29, 2024.
• The company has included new certifications by the principal executive officer and principal financial officer as exhibits to this amendment.
• The amendment does not include any changes to the financial statements or disclosures related to internal controls.
• The company's common stock outstanding as of April 23, 2024, was 28,804,643 shares.
• The aggregate market value of voting and non-voting common equity held by non-affiliates was $20,042,404 as of the last business day of the company's most recently completed second fiscal quarter.

Sentiment

Score: 6

Explanation: The document is a regulatory filing, so the sentiment is neutral. The amendment indicates a need for correction, which is not ideal, but the company is taking steps to rectify the situation. The company has a good governance structure and is taking steps to incentivize employees.

Positives

• The company has a clear corporate governance structure with an independent audit committee.
• The company has established stock incentive plans to attract and retain talent.
• The company has disclosed all related party transactions and has a policy to ensure fair terms.
• The company has complied with Section 16(a) of the Exchange Act for the year ended December 31, 2023.
• The company has adopted a Code of Ethics applicable to all employees, executive officers and directors.

Negatives

• The company had to amend its annual report to include previously omitted information, which could raise concerns about internal controls.
• The company has not yet commenced the payment of non-executive directors, but intends to do so in the future.
• The company has a significant amount of shares held by Bios Equity Entities, which could lead to potential conflicts of interest.

Risks

• The company operates in a competitive and rapidly changing environment, and new risks may emerge.
• The company's forward-looking statements may not be achieved due to various risks and uncertainties.
• The company's financial results may differ materially from those anticipated in forward-looking statements.
• The company's reliance on key personnel could pose a risk if they were to leave the company.
• The company's stock price could be affected by the actions of major shareholders.

Future Outlook

The company intends to commence the payment of non-executive directors, including the payment of cash and equity awards, or a combination of both, but has not adopted any such plans or policies as of this date.

Management Comments

• We believe that Mr. Salvas experience as a senior executive, venture capitalist and investment banker in the biotech and pharmaceutical industries qualifies him to serve on our Board.
• We believe that Mr. Whitfills strong background in entrepreneurship and in the biotech and healthcare industries qualifies him to serve on our Board.
• We believe that Dr. McClarys medical and scientific expertise as a physician-scientist coupled with his experience working in the venture capital industry qualifies him to serve on our Board.
• We believe that Ms. Ryan is qualified to serve as a member of our Board because of her experience and knowledge of corporate finance, mergers and acquisitions, corporate governance, as well as other operational, financial and accounting matters gained as a past and present executive officer and/or director of other public and private companies.
• We believe that Mr. Schroers strong background holding leadership positions in the biotechnology industry and almost 30 years of investing in the life sciences sector qualifies him to serve on our Board.

Industry Context

This amendment is a standard regulatory filing for a public company, ensuring transparency and compliance with SEC regulations. The details on executive compensation and board composition are typical for a company in the biotechnology sector.

Comparison to Industry Standards

• The executive compensation packages, including base salaries, bonuses, and stock options, are generally in line with industry standards for biotechnology companies of similar size and stage.
• The board composition, with a majority of independent directors, aligns with best practices in corporate governance.
• The use of stock incentive plans is a common practice in the biotech industry to attract and retain talent.
• The engagement of a reputable audit firm like Grassi & Co. is consistent with industry norms for public companies.
• The related party transactions, such as the convertible notes issued to existing stockholders, are not uncommon in early-stage biotech companies, but require careful scrutiny to ensure fairness and transparency.

Related Party Transactions

• In September 2022, the company issued unsecured convertible promissory notes in the aggregate principal amount of $4.35 million to five existing stockholders, including $4 million to Bios entities.
• In December 2019, the company entered into a Joint Development Agreement with Bayer, which includes a one-time payment and reimbursement for development costs.
• In September 2020, Bayers venture capital group, LEAPS by Bayer, purchased $8 million of the company's Series B preferred stock.

Stakeholder Impact

• Shareholders will have more complete information about the company's directors, executive officers, and corporate governance.
• Employees will be impacted by the executive compensation and stock incentive plans.
• The company's relationships with Bayer and Bios Equity Entities could impact future collaborations and funding.

Next Steps

• The company intends to commence the payment of non-executive directors.
• The company will continue to file reports on Forms 10-K, 10-Q, and 8-K with the SEC.

Key Dates

Keywords

Azitra, Annual Report, Amendment, Directors, Executive Officers, Corporate Governance, Executive Compensation, Stock Options, Audit Committee, Related Party Transactions, Bios Equity, Grassi & Co.